Saturday, February 21, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Financial Markets

Where are the Physician Investors?

They come in all shapes and sizes

Arlen Meyers by Arlen Meyers
February 25, 2024
in Financial Markets
0
Where are the Physician Investors

Airfocus

Physician entrepreneurs come in many assorted flavors, like technopreneurs, social entrepreneurs, intrapreneurs and consultant/freelancer/service providers. Another role they play in the medical innovation supply chain is as a physician investor. Like any other investor, they use different platforms to achieve their financial goals, using mutual fund portfolios, investing as an angel, or participating in angel networks or investment syndicates.

A more recent trend is doctors becoming investment bankers or venture capital general or limited partners, consultants and advisors.

Many biomedical and clinical startups target health professionals for early seed stage investment. However, the doctor funded startup comes with some baggage and risks beyond the unusual ones.

If you are considering raising money from doctors, dentists, nurses, pharmacists or other health professionals, here are some tips:

  1. As an outsider (non-MD or medical professional degree holder) , it is difficult sometimes to be a trusted member of the inner sanctum, particularly when others think you are only there to get their money. Relationships take time to develop, time you might not have as your burn rate meter is running out. Be strategic and honest but focus on the few investors who show a genuine interest. Even better, develop the networks beforehand so you have some comfort level when it’s time to make the ask.
  2. Find a reputable navigator, mentor, connector, or maven to introduce you those who might have an interest in your idea based on previous investment history or record of accomplishment
  3. Do your homework on national angel networks that specialize in biomedical clinical or digital health investments and are composed of members in the health professions. Some specialize in creating investor networks that include just doctors investing in ideas from other doctors. Check www.angelcapitalassociation.org or www.gust.com or www.ii4change.com (Tell them SoPE (The Society of Physician Entrepreneurs) sent you)
  4. Some doctors are angels, investment bankers or work with private equity firms or advise family offices, so expand your universe of sources as part of your research. Secondary sources might include wealth managers or others in the financial services industry.
  5. Join and participate in interdisciplinary, eclectic regional innovation ecosystems where you are more likely to meet and interact with investor physicians.
  6. Go where the money is. Many physician investors like to stay off the radar. Some, on the other hand, make their investment propensities more public. You might find more success in vacation, or second home communities or social events supported by high-net-worth individuals
  7. Attend hospital or community resource fundraisers to show your support and find a seat next to your new investor. Consider college alumni events as another way to link. Get more involved in voluntary activities.
  8. Find companies like yours that were able to raise money in early seed rounds from doctors. Contact the CEO and pick their brains for tips on technique and ways to access their network.
  9. Be sure your investment pitch is ready for prime time since you will only have one chance to make a first impression. Here are the biggest reasons why it might not be. You never know when and where you might meet your next investor, doctor or not.
  10. Be sure you understand the issues around raising private money and the impact of recent equity-crowdfunding regulations. Talk to your legal and accounting advisors and plan.

Many people think that doctors are willing and eager to give you their money because 1) they have a firm understanding of the clinical challenge you are trying to solve or the opportunity you are trying to pursue, 2) they are savvy investors or 3) they have networks and connections and can help spread the word and create buzz around your idea. Think again. While I vigorously disagree with the conventional wisdom that “doctors are lousy business people”, in most cases they are like every other investor who is looking for the quickest return on investment with commensurate risk. Connecting and building a trusted relationship is the first step. Success or failure sits on that foundation.

Source: Arlen Meyers MD MBA Substack
ShareTweet
Arlen Meyers

Arlen Meyers

Arlen Meyers, MD, MBA is the President and CEO of the Society of Physician Entrepreneurs on Substack.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Prevention Gap in Dementia Care

    The Prevention Gap in Dementia Care

    0 shares
    Share 0 Tweet 0
  • Healthcare Natural Rights

    0 shares
    Share 0 Tweet 0
  • The Staffing Equation That Doesn’t Balance

    0 shares
    Share 0 Tweet 0
  • Healthcare in Space

    1 shares
    Share 0 Tweet 0
  • Heat Safety Tips Every Pregnant Mother Should Know

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy